Seliforant (also known as SENS-111 or UR-63325) is an investigational small-molecule drug developed by Sensorion (originally by Palau Pharma) for inner-ear/vestibular disorders, particularly vertigo and vestibular neuritis, and has also been cited as having potential for tinnitus and hearing loss indications.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.